Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EEF2K | O00418 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650271 | 0.89 | BDKRB1 (0.45) | ALDH1A1LMNAATML3MBTL1BDKRB1 | |
| SCHEMBL4650884 | 0.88 | PTPN1 (0.49) | ALDH1A1LMNAATML3MBTL1PTPN1 | |
| SCHEMBL4651105 | 0.88 | PTPN1 (0.44) | ALDH1A1LMNAL3MBTL1BDKRB1PTPN1 | |
| SCHEMBL7054363 | 0.87 | PTPN1 (0.46) | ALDH1A1LMNAL3MBTL1BDKRB1PTPN1 | |
| SCHEMBL4651379 | 0.87 | ALDH1A1 (0.58) | ALDH1A1LMNAPOLBPTPN1 | |
| SCHEMBL4650872 | 0.84 | ALDH1A1 (0.60) | ALDH1A1POLBPTPN1 | |
| SCHEMBL7050019 | 0.83 | ALDH1A1 (0.54) | ALDH1A1POLBPTPN1 | |
| SCHEMBL4650322 | 0.82 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL4651316 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNABDKRB1POLBKDM4E | |
| SCHEMBL4651106 | 0.79 | PTPN1 (0.51) | LMNAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | claimed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | ALDH1A1 446/4885EEF2K 2692/4885LMNA 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.